Retatrutide dosage
Also known as: LY3437943
What is Retatrutide?
Retatrutide (development code LY3437943) is an experimental once-weekly injectable drug from Eli Lilly. It is not approved for any use, and its maker states it cannot be legally sold or marketed for human use.
How it works
It is a triple agonist: one molecule that activates the receptors for three hormones, GIP, GLP-1 and glucagon. GLP-1 is a natural regulator of appetite and calorie intake.
What the evidence shows
Retatrutide is not approved by the FDA. In a Phase 2 trial of 338 adults published in 2023, average weight change at 48 weeks was -24.2% at the highest dose versus -2.1% with placebo. Lilly has announced Phase 3 topline results that are not yet peer-reviewed: at 80 weeks, losses of up to 20.8% versus 4.0% with placebo in 1,152 adults with type 2 diabetes, and up to 22.6% versus 3.2% in 1,949 adults with severe obesity and cardiovascular disease. A 68-week trial in 445 adults with knee osteoarthritis reported 28.7% versus 2.1%. Long-term safety is unknown.
Reported side effects
- Diarrhea
- Nausea
- Constipation
- Decreased appetite
- Vomiting
- Dysesthesia (abnormal skin sensations)
- Urinary tract infections
- Dose-dependent increase in heart rate
Cautions
- There is no approved prescribing information, so contraindications and warnings have not been formally established.
- In Phase 3 trials, up to 13.5% to 18.2% of participants on the highest dose stopped treatment because of adverse events.
- The FDA states that retatrutide cannot be used in compounding because it is not a component of an FDA-approved drug and has not been found safe and effective for any condition.
- The FDA has warned companies selling retatrutide labeled for research purposes and urges consumers not to buy these products.
Legal and regulatory status
Not FDA-approved for any use. Eli Lilly has said it plans to submit an application to the FDA in the first quarter of 2027. WADA's Prohibited List includes a class (S0) for non-approved substances, which are prohibited at all times; athletes should confirm status with their anti-doping organization.
Common questions
Is retatrutide FDA-approved?
No. Retatrutide is an investigational drug still in Phase 3 trials. Eli Lilly has said it plans to file for US approval in the first quarter of 2027, and approval is not guaranteed.
How much weight did people lose in retatrutide trials?
In a 48-week Phase 2 trial, average weight change was -24.2% at the highest dose versus -2.1% with placebo. Company-reported Phase 3 averages at the highest dose range from 20.8% to 28.7% over 68 to 80 weeks, and are not yet peer-reviewed.
Is it legal to buy retatrutide online?
Its maker states it cannot be legally sold or marketed for human use, and the FDA says it cannot be used in compounding. The FDA has warned sellers of products labeled for research use and urges consumers not to buy them.
Sources
- PubMed / NEJM: Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (2023)
- Eli Lilly: Retatrutide successful in two additional Phase 3 obesity trials (July 23, 2026)
- The Pharmaceutical Journal: Investigational weight-loss drug trial shows average reduced body weight of almost 30% (December 2025)
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
- FDA: Zepbound (tirzepatide) prescribing information
- WADA: The Prohibited List
Articles about Retatrutide
CommentaryRetatrutide: Why This Triple-Action Peptide Could Change the Future of Weight Loss
Retatrutide reviews and Q&A
Get the printable dosing chart
All 50 peptides on a few pages, as a PDF. We’ll also email you when a peptide’s approval status or dosing changes.
More in Weight & metabolic
Compare Retatrutide
Reference only, not medical advice. Doses marked FDA-approved come from the US prescribing label. Doses marked Not approved are ranges reported from small studies or community use and have not been established as safe or effective in humans. Check anything here with a licensed clinician before acting on it. Read the full disclaimer.